002399.SZ
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 10.00
−4.49%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 5.2B | 5.5B | 5.3B | 5.4B | 7.2B |
| Cost of Revenue | 3.5B | 3.7B | 3.5B | 3.6B | 4.8B |
| Gross Profit | 1.7B | 1.7B | 1.8B | 1.8B | 2.3B |
| Operating Expenses | |||||
| R&D Expense | 205.8M | 226.2M | 212.0M | 182.4M | 252.1M |
| SG&A Expense | 31.7M | — | — | — | — |
| General & Admin Expense | 303.7M | 419.3M | 397.3M | 458.6M | 457.2M |
| Selling & Marketing Expense | 406.6M | 428.5M | 389.4M | 517.4M | 518.5M |
| Other Expenses | 277.3M | — | — | — | — |
| Total Operating Expenses | 1.4B | 1.0B | 1.1B | 1.3B | 1.3B |
| Cost and Expenses | 4.9B | 4.8B | 4.7B | 4.9B | 6.1B |
| Operating Income (EBIT) | 205.8M | 410.0M | 741.3M | (860.9M) | 828.6M |
| Non-Operating | |||||
| Interest Income | 12.1M | — | — | — | — |
| Interest Expense | 12.6M | — | — | — | — |
| Net Interest Income | (440.7K) | — | — | — | — |
| Other Non-Op Income/Expense | 90.3K | — | — | — | — |
| Non-Operating Income (excl Interest) | (76.8M) | — | — | — | — |
| EBT (Pre-Tax Income) | 199.1M | 402.2M | 726.2M | (928.3M) | 829.9M |
| Income Tax Expense | 32.1M | 59.6M | 101.3M | (126.2M) | 114.8M |
| Bottom Line | |||||
| Net Income | 202.9M | 349.5M | 646.7M | (783.3M) | 727.4M |
| Earnings from Cont. Ops | 196.4M | 342.6M | 624.9M | (802.2M) | 715.0M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 202.9M | 349.5M | 646.7M | (783.3M) | 727.4M |
| Per Share | |||||
| Basic EPS | CN¥0.14 | CN¥0.24 | CN¥0.44 | (CN¥0.53) | CN¥0.50 |
| Diluted EPS | CN¥0.14 | CN¥0.24 | CN¥0.44 | (CN¥0.53) | CN¥0.50 |
| Revenue Per Share | CN¥3.57 | CN¥3.73 | CN¥3.60 | CN¥3.71 | CN¥4.88 |
| Shares | |||||
| Basic Shares Outstanding | 1.5B | 1.5B | 1.5B | 1.5B | 1.5B |
| Diluted Shares Outstanding | 1.5B | 1.5B | 1.5B | 1.5B | 1.5B |
| Profitability Metrics | |||||
| EBITDA | 219.3M | 759.5M | 1.0B | (509.6M) | 1.1B |
| D&A | 95.4M | 349.5M | 307.7M | 351.3M | 284.4M |
| EBIT | 123.9M | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026